Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

romidepsin 8Vincristine 6Cyclophosphamide 6Specimen Handling 5Rituximab 5Biopsy 5fludarabine 4Prednisone 4Methotrexate 4Magnetic Resonance Spectroscopy 4Lactones 4Doxorubicin 4Depsipeptides 4ruxolitinib 3duvelisib 3belinostat 3Nivolumab 3Etoposide 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Bortezomib 3Azacitidine 3tazemetostat 2sodium-iodide symporter 2pegaspargase 2merphos 2liposomal doxorubicin 2cemiplimab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡